Urology News and Research

Latest Urology News and Research

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Weight-loss surgery may reduce lower urinary tract symptoms

Metabolic syndrome is linked with an increased frequency and severity of lower urinary tract symptoms, but weight loss surgery may lessen these symptoms. The findings, which come from two studies published in BJU International, indicate that urinary problems may be added to the list of issues that can improve with efforts that address altered metabolism.

8 Dec 2014

Nivolumab drug highly effective for Hodgkin's lymphoma

A phase I clinical trial of nivolumab found that the immune-boosting drug is a highly effective therapy for Hodgkin's lymphoma. The multi-institution study, led by Mayo Clinic, indicated that the drug was safe and led to an 87 percent response rate in patients who had failed on other treatments.

7 Dec 2014

Study links poor semen quality to higher risk of various health conditions

A study of more than 9,000 men with fertility problems has revealed a correlation between the number of different defects in a man's semen and the likelihood that the man has other health problems.

6 Dec 2014

Malnutrition predicts long-term survival in elderly patients undergoing Whipple procedure

Malnutrition is an important factor predicting long-term survival in older patients undergoing pancreaticoduodenectomy (PD) (commonly called the Whipple procedure) to treat benign tumors and cysts of the pancreas as well as pancreatitis, according to new study results published in the December issue of the Journal of the American College of Surgeons.

6 Dec 2014

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.

5 Dec 2014

Abstinence-induced changes in the brain could help predict relapse in smokers

Quitting smoking sets off a series of changes in the brain that Penn Medicine researchers say may better identify smokers who will start smoking again—a prediction that goes above and beyond today's clinical or behavioral tools for assessing relapse risk.

5 Dec 2014

New drug offers hope for victims of spinal cord injury

Scientist in the U.S have developed a drug that could help paralysed victims of spinal cord injury regain their ability to move.

4 Dec 2014

New chemical compound shows promise in restoring function lost to spinal cord injury

Case Western Reserve scientists have developed a new chemical compound that shows extraordinary promise in restoring function lost to spinal cord injury. The compound, which the researchers dubbed intracellular sigma peptide (ISP), allowed paralyzed muscles to activate in more than 80 percent of the animals tested.

4 Dec 2014

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital.

4 Dec 2014

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

National guidelines recommend that men with low- and intermediate -risk prostate cancer and life expectancies of less than 10 years should not be treated with radiation or surgery, since they are unlikely to live long enough to benefit from treatment. Yet it is unknown whether such men are unnecessarily receiving these aggressive local treatments, putting them at risk for potentially debilitating side effects.

2 Dec 2014

Sanovas's endoscopic imaging platform recognized by Frost & Sullivan

Based on its recent analysis of the endoscopic imaging market, Frost & Sullivan recognizes Sanovas Inc. with the 2014 Global Frost & Sullivan Award for New Product Innovation Leadership. In a market where spiralling healthcare costs impact the entire spectrum of stakeholders, Sanovas's ground-breaking endoscopic platform, MicroCam, provides the functionality of a high-end, flexible endoscope without the accompanying cost and maintenance burden.

1 Dec 2014

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

The U.S. Food and Drug Administration is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids, which is in keeping with Kalorama Information's view that in the female health market there is much room for improvement both in the development of products and the treatment of diseases.

29 Nov 2014

Immune-suppressing protein may predict how patients respond to treatment

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.

27 Nov 2014

Good Samaritan Hospital receives $417,560 grant to implement telemedicine program

The U.S. Department of Agriculture (USDA) Rural Development awards Good Samaritan Hospital, a prominent downtown Los Angeles hospital, a $417,560 grant to implement a telemedicine program that will connect members of the medical staff at Good Samaritan Hospital with public health and primary care providers and their patients at six Public Health sites on the island of Guam.

27 Nov 2014

Surprise WHI finding points to age, not menopause, as a risk factor for pelvic organ prolapse

Removing ovaries at hysterectomy does not increase a woman's risk of pelvic organ prolapse after menopause. In fact, removing ovaries lowers the risk of prolapse. This surprising finding from a Women's Health Initiative study was published online this week in Menopause, the journal of The North American Menopause Society.

27 Nov 2014

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists from Queen Mary University of London have made a breakthrough in developing a new therapy for advanced bladder cancer - for which there have been no major treatment advances in the past 30 years.

26 Nov 2014

Minimally invasive surgeries successfully performed at Policlinico Gemelli in Rome with ALF-X system

It's called ALF-X and it's the innovative robotic surgical system being used by gynaecological surgeons at the A. Gemelli University Polyclinic in Rome, which has been in operation in the surgical field for a year in the Department for the Protection of Health of Women, Newborns, Children and Adolescents, directed by professor Giovanni Scambia.

26 Nov 2014

Perc NGage® and Perc NCompass® nitinol stone extractors launched by Cook Medical

Urologists now have new options for stone extraction devices when performing percutaneous nephrolithotomy (PCNL), as Cook Medical is launching the Perc NGage® and Perc NCompass® nitinol stone extractors today. The new products complement the Perc NCircle®, which has been on the market since 2002 and was the first nitinol extraction device for percutaneous procedures. Cook Medical was the first company to incorporate nitinol into its stone extraction devices.

From COOK MEDICAL INC. 26 Nov 2014

Long-term T therapy in hypogonadal men is safe, does not increase PCa risk, study finds

Testosterone (T) therapy is routinely used in men with hypogonadism, a condition in which diminished function of the gonads occurs. Although there is no evidence that T therapy increases the risk of prostate cancer (PCa), there are still concerns and a paucity of long-term data.

25 Nov 2014

Urology News and Research

Latest Urology News and Research

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Weight-loss surgery may reduce lower urinary tract symptoms

Nivolumab drug highly effective for Hodgkin's lymphoma

Study links poor semen quality to higher risk of various health conditions

Malnutrition predicts long-term survival in elderly patients undergoing Whipple procedure

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Abstinence-induced changes in the brain could help predict relapse in smokers

New drug offers hope for victims of spinal cord injury

New chemical compound shows promise in restoring function lost to spinal cord injury

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

Sanovas's endoscopic imaging platform recognized by Frost & Sullivan

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

Immune-suppressing protein may predict how patients respond to treatment

Good Samaritan Hospital receives $417,560 grant to implement telemedicine program

Surprise WHI finding points to age, not menopause, as a risk factor for pelvic organ prolapse

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Minimally invasive surgeries successfully performed at Policlinico Gemelli in Rome with ALF-X system

Perc NGage® and Perc NCompass® nitinol stone extractors launched by Cook Medical

Long-term T therapy in hypogonadal men is safe, does not increase PCa risk, study finds

Forensics and toxicology - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Urology News and Research

Latest Urology News and Research

Forensics and toxicology - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in